Papers 7

1. HIV-1 Tat protein transduction domain peptide facilitates gene transfer in combination with cationic liposomes.
   Hyndman L et al., J Control Release. 2004 Oct 19;99(3):435-44.
2. Potent stimulation of gene expression by histone deacetylase inhibitors on transiently transfected DNA.
   Nan X et al., Biochem Biophys Res Commun. 2004 Nov 5;324(1):348-54.
3. Differential global gene expression in cystic fibrosis nasal and bronchial epithelium.
   Ogilvie V et al., Genomics. 2011 Nov;98(5):327-36. doi: 10.1016/j.ygeno.2011.06.008. Epub 2011 Jul 2.
4. Pre-clinical evaluation of three non-viral gene transfer agents for cystic fibrosis after aerosol delivery to the ovine lung.
   McLachlan G et al., Gene Ther. 2011 Oct;18(10):996-1005. doi: 10.1038/gt.2011.55. Epub 2011 Apr 21.
5. Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis
   Alton EW et al., Thorax. 2017 Feb;72(2):137-147. doi: 10.1136/thoraxjnl-2016-208406.
6. A randomised, double-blind, placebo-controlled trial of repeated nebulisation of non-viral cystic fibrosis transmembrane conductance regulator (CFTR) gene therapy in patients with cystic fibrosis.
   Alton EW et al., Efficacy and Mechanism Evaluation (2016) Volume: 3 Issue: 5
7. Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial.
   Alton EW et al., Lancet Respir Med. 2015 Sep;3(9):684-91. doi: 10.1016/S2213-2600(15)00245-3. Epub 2015 Jul 3.

Abstracts 1

1. Moving lentiviral-based gene therapy into a first-in-man CF trial.
   Griesenbach U et al.,The North American Cystic Fibrosis Conference (2015)